1. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- Author
-
Santoro, A, Rimassa, L, Borbath, I, Daniele, B, Salvagni, S, Van Laethem, Jl, Van Vlierberghe, H, Trojan, J, Kolligs, Ft, Weiss, A, Miles, S, Gasbarrini, Antonio, Lencioni, M, Cicalese, L, Sherman, M, Gridelli, C, Buggisch, P, Gerken, G, Schmid, Rm, Boni, C, Personeni, N, Hassoun, Z, Abbadessa, G, Schwartz, B, Von Roemeling, R, Lamar, Me, Chen, Y, Porta, C., Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Santoro, A, Rimassa, L, Borbath, I, Daniele, B, Salvagni, S, Van Laethem, Jl, Van Vlierberghe, H, Trojan, J, Kolligs, Ft, Weiss, A, Miles, S, Gasbarrini, Antonio, Lencioni, M, Cicalese, L, Sherman, M, Gridelli, C, Buggisch, P, Gerken, G, Schmid, Rm, Boni, C, Personeni, N, Hassoun, Z, Abbadessa, G, Schwartz, B, Von Roemeling, R, Lamar, Me, Chen, Y, Porta, C., and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)
- Abstract
Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown promising antitumour activity in hepatocellular carcinoma as monotherapy and in combination with sorafenib. We aimed to assess efficacy and safety of tivantinib for second-line treatment of advanced hepatocellular carcinoma.
- Published
- 2013